Many newly defined tumour antigens are 'self' proteins. Immunizing cancer patients against these antigens may be difficult due to tolerance. The HER-2/neu oncogenic protein is such a 'self' tumour antigen. Rat neu is homologous with human HER-2/neu and provides a model system for studying vaccination strategies. Rats are tolerant to rat neu. Vaccination with this 'self' protein elicits no detec...

Treatment of human epidermal growth factor receptor 2 (HER2/neu)-expressing breast cancer patients with a monoclonal antibody (mAb) directed against HER2/neu improves the outcome of chemotherapy. In cases in which remission is observed, antibody-dependent cell-mediated cytotoxicity (ADCC) seems to be one of the main mechanisms of anti-HER2/neu mAb action, implicating Fc gamma receptors (Fc gamm...

Overexpression of the epithelial specific matrix metalloproteinase matrilysin (MAT) has been correlated with enhanced tumorigenicity and tumor cell invasion using in vitro model systems. We have determined the effects of MAT expression on the development of mammary tumorigenesis using transgenic mice that express human MAT under the control of the mouse mammary tumor virus (MMTV)-long terminal ...

The clinical effects of targeting Her-2/neu in prostate carcinoma are not known. This study explores the feasibility of molecular profiling to determine the correlation between Her-2/neu expression and hormonal sensitivity. Patients with progressive androgen-independent prostate carcinoma were eligible to participate in the study. Her-2/neu expression was assessed on pretreatment tissue specime...

BACKGROUND HER2/neu overexpression and/or amplification has been widely studied in a number of solid tumors, primarily in the breast. In gynecologic neoplasms, determination of HER2/neu status has not been well studied as a predictive biomarker in anti-HER2/neu treatment. METHODS We systematically evaluated the HER2/neu reactions by immunohistochemistry and fluorescent in situ hybridization i...

Amplification and overexpression of the HER-2/neu proto-oncogene frequently coincide with an aggressive clinical course of certain human adenocarcinomas. To assess whether HER-2/neu plays a rate-limiting role in ovarian cancer, we used human SK-OV-3 ovarian cancer cells as a model. We applied a conditional mRNA depletion strategy of HER-2/neu with anti-HER-2/neu-targeted hammerhead ribozymes ex...

OBJECTIVE We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. Additionally, we evaluated relationship of HER2/neu levels with tumor stage, grade, recurrence and progression. MATERIALS AND METHODS Fourty-four patients with primary non-muscle invasive bladder tumors (Group 2) and 40 healthy control group (Grou...

ownload tment of human epidermal growth factor receptor 2 (HER2/neu)-expressing breast cancer patients with oclonal antibody (mAb) directed against HER2/neu improves the outcome of chemotherapy. In cases in remission is observed, antibody-dependent cell-mediated cytotoxicity (ADCC) seems to be one of the echanisms of anti-HER2/neu mAb action, implicating Fcγ receptors (FcγRs) in this tumoricida...

[1] L. Ahlfors and L. Bers, Riemann’s mapping theorem for variable metrics, Ann. Math. 72 (1960), pp. 413– 429 [2] F. Bonahon, Bouts des variétés hyperboliques de dimension 3, Ann. Math. 124 (1986), pp. 71–158 [3] D. Epstein and A. Marden, Convex hulls in hyperbolic space, a theorem of Sullivan, and measured pleated surfaces, in Analytical and Geometric Aspects of Hyperbolic Space, LMS 111 (198...